{"id":3722,"date":"2026-11-02T15:02:01","date_gmt":"2026-11-02T15:02:01","guid":{"rendered":"https:\/\/indiamedicine.org\/?p=3722"},"modified":"2026-11-02T15:02:01","modified_gmt":"2026-11-02T15:02:01","slug":"india-drug-patent-overhaul-generic-buyer-guide-2026","status":"publish","type":"post","link":"https:\/\/indiamedicine.org\/?p=3722","title":{"rendered":"Understanding India&#8217;s Drug Patent Overhaul: A Generic Buyer&#8217;s Guide 2026"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">India supplies roughly a fifth of the world&#8217;s generic medicines by volume, and much of that supply depends on a single legal question: when does a medicine actually become free to copy? For international buyers, importers and pharmacy operators, the answer changed shape in October 2026, when India&#8217;s patent office published new draft examination guidelines designed to block <em>evergreening<\/em> &mdash; the practice of extending market monopoly through minor modifications to an existing drug.<\/p>\n\n\n<p class=\"wp-block-paragraph\">This guide explains what the draft guidelines say, why courts matter as much as regulators, and how buyers should read patent status when sourcing Indian generics.<\/p>\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n<h2 class=\"wp-block-heading\">&#x1f4cc; What Is Evergreening, and Why Does It Matter to Buyers?<\/h2>\n\n\n<p class=\"wp-block-paragraph\">A pharmaceutical patent in India lasts 20 years. As that term approaches expiry, originator companies have historically filed fresh patents on incremental variations &mdash; a new salt, a new crystal form (polymorph), a purified form, a derivative or a new dosage &mdash; in order to keep generics off the market for additional years. This is what the industry calls evergreening.<\/p>\n\n\n<p class=\"wp-block-paragraph\">The cost to buyers is direct. Every year of extended exclusivity is a year without price competition. India&#8217;s safeguard against this is <strong>Section 3(d) of the Patents Act<\/strong>, which bars patents on mere discovery of a new form of a known substance unless the applicant can show <em>enhanced therapeutic efficacy<\/em>. When that barrier holds, generic entry arrives on schedule and prices fall sharply; when litigation delays it, buyers keep paying originator prices.<\/p>\n\n\n<p class=\"wp-block-paragraph\">A concrete illustration from the current cycle: when Roche&#8217;s patent on risdiplam (Evrysdi), used for spinal muscular atrophy, was successfully challenged, Natco Pharma priced its version at about &#8377;15,900 per bottle against roughly &#8377;6.2 lakh per bottle for the originator &mdash; as reported by <em>Business Standard<\/em> (March 2026). That gap is what patent outcomes actually look like on an invoice.<\/p>\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n<h2 class=\"wp-block-heading\">&#x1f3db;&#xfe0f; What India&#8217;s New Draft Patent Guidelines Actually Change<\/h2>\n\n\n<p class=\"wp-block-paragraph\">The draft guidelines were issued by the Office of the Controller General of Patents, Designs and Trade Marks, under the Ministry of Commerce and Industry, and were reported by <em>LiveMint<\/em> on 16 October 2026. They replace the 2014 examination guidelines and fold major court decisions from 2013 to 2026 directly into routine patent examination.<\/p>\n\n\n<p class=\"wp-block-paragraph\">The substantive changes most relevant to the generic supply chain are:<\/p>\n\n\n<ul class=\"wp-block-list\"><li><strong>Comparative data is now mandatory.<\/strong> Applicants claiming patents on new salts, crystal structures, pure forms or derivatives of known substances must supply comparative research data showing a significant increase in therapeutic performance.<\/li><li><strong>Commercial advantages do not count.<\/strong> Longer shelf life, easier manufacturing or faster absorption will not satisfy the therapeutic-efficacy standard unless supported by test data in living models demonstrating superior treatment of disease.<\/li><li><strong>A seven-pillar novelty test.<\/strong> Examiners must apply the Delhi High Court&#8217;s framework, assessing each claim on its own rather than stitching together separate earlier publications.<\/li><li><strong>A structured obviousness test.<\/strong> Court-approved multi-step tests are to be used as flexible guides rather than fixed formulas, and without the benefit of hindsight.<\/li><li><strong>Markush claims are restricted.<\/strong> Broad genus claims over large theoretical chemical families must now disclose representative compounds, working preparation steps and biological test results &mdash; or face refusal.<\/li><li><strong>Combination drugs face a higher bar.<\/strong> Under Section 3(e), fixed-dose combinations are rejected unless clinical trials show a combined benefit greater than the individual actions of the ingredients.<\/li><li><strong>Section 3(i) is strictly enforced.<\/strong> Patents on medical, surgical or curative treatment <em>methods<\/em> remain barred, while physical diagnostic machines, instruments and screening kits stay patentable.<\/li><li><strong>Biological ingredients<\/strong> require declared origin with deposited physical samples, and applicants cannot broaden the scope of original claims during appeals.<\/li><\/ul>\n\n\n<p class=\"wp-block-paragraph\">Notably, the patent office framed the update as a consistency measure: harmonising examination practice across technical officers and raising examination standards, rather than as a new statute. That distinction matters &mdash; guidelines bind examiners procedurally, but they do not amend the Patents Act.<\/p>\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n<h2 class=\"wp-block-heading\">&#x2696;&#xfe0f; Courts, Not Just Regulators, Decide When Generics Launch<\/h2>\n\n\n<p class=\"wp-block-paragraph\">This is the part most sourcing guides omit. Even a legally weak secondary patent can delay a generic competitor, because originators routinely seek ad-interim injunctions in infringement suits before the High Court. As Rahul Hingmire of Vis Legis Law Practice told <em>Business Standard<\/em>, &ldquo;even a six-to-twelve-month delay can significantly affect market access.&rdquo;<\/p>\n\n\n<p class=\"wp-block-paragraph\">The recent High Court record shows how these disputes resolve:<\/p>\n\n\n<ul class=\"wp-block-list\"><li><strong>Semaglutide (2026):<\/strong> The Delhi High Court allowed Dr. Reddy&#8217;s Laboratories to manufacture semaglutide in India, but restricted sales and exports to jurisdictions where Novo Nordisk holds no patent protection. Novo Nordisk had relied on secondary patents filed in December 2025 after the primary semaglutide patent expired in India, China and Brazil in March.<\/li><li><strong>Risdiplam (2025):<\/strong> The Delhi High Court permitted Natco Pharma to launch a generic version of Roche&#8217;s spinal muscular atrophy therapy, finding Roche&#8217;s patent was a minor tweak designed to prolong market control. The Supreme Court later dismissed Roche&#8217;s challenge.<\/li><li><strong>Nivolumab (2025):<\/strong> The Delhi High Court allowed Zydus Lifesciences to manufacture and sell biosimilar versions of Bristol Myers Squibb&#8217;s cancer immunotherapy, holding that access to affordable treatment could not be denied to patients. Zydus subsequently launched at &#8377;13,950 and &#8377;28,950 for the two dosage forms, against originator pricing of roughly &#8377;45,000 to &#8377;1 lakh per vial.<\/li><\/ul>\n\n\n<p class=\"wp-block-paragraph\">There is also a procedural shift worth tracking: a Delhi High Court ruling held that a revocation challenge under Section 64 of the Patents Act can continue even after the patent has expired, particularly where damages are claimed in an infringement suit &mdash; and if a patent is revoked, the invalidation operates retrospectively from the date of grant. In practical terms, a late challenge can still unwind an earlier monopoly.<\/p>\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n<h2 class=\"wp-block-heading\">&#x1f50d; How Buyers Should Read Patent Status When Sourcing Indian Generics<\/h2>\n\n\n<p class=\"wp-block-paragraph\">Patent status is a sourcing risk factor, not a paperwork detail. A generic that is legal to manufacture may still be restricted in where it can be sold. Work through these checks before committing to a purchase order or an export contract:<\/p>\n\n\n<ul class=\"wp-block-list\"><li><strong>1. Identify the molecule, not the brand.<\/strong> Patent status attaches to the active pharmaceutical ingredient and its specific forms, not to a trade name. Confirm the exact salt, polymorph and dosage form in the product you are buying.<\/li><li><strong>2. Ask whether the primary patent has expired in your destination market.<\/strong> Expiry is territorial. Semaglutide&#8217;s primary patent lapsed in India, China and Brazil in March 2026 &mdash; that says nothing about status in the EU, the UK or the US.<\/li><li><strong>3. Ask specifically about secondary patents and pending litigation.<\/strong> A manufacturer may be permitted to manufacture while being restricted on sale or export, exactly as happened with Dr. Reddy&#8217;s semaglutide ruling. Confirm the scope of any court order in writing.<\/li><li><strong>4. Distinguish generics from biosimilars.<\/strong> Biologic products such as nivolumab follow a different regulatory and litigation pathway than small-molecule generics. Do not treat a biosimilar approval as equivalent to a generic ANDA-type filing.<\/li><li><strong>5. Require the regulatory approval document, not a marketing claim.<\/strong> Ask for the CDSCO approval or import registration reference and confirm the approved indication and dosage forms.<\/li><li><strong>6. Verify the manufacturer, not just the product.<\/strong> A valid patent position does not guarantee GMP compliance. Site-level verification remains a separate exercise, and the two should never be conflated.<\/li><li><strong>7. Document your due diligence.<\/strong> For regulated-market importers, evidence that you checked patent status before purchase is a defensible record. Undocumented reliance on a supplier&#8217;s assurance is not.<\/li><\/ul>\n\n\n<p class=\"wp-block-paragraph\">For source-level verification of a distributor&#8217;s standing before you place an order, refer to the <a href=\"https:\/\/indiamedicine.org\/?page_id=1454\">IMSDA&#8217;s verified member directory<\/a>, which lists verified and reliable pharmaceutical distributors.<\/p>\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n<h2 class=\"wp-block-heading\">&#x26a0;&#xfe0f; What the Draft Guidelines Do <em>Not<\/em> Do<\/h2>\n\n\n<p class=\"wp-block-paragraph\">Three cautions for anyone treating this as a settled liberalisation:<\/p>\n\n\n<ul class=\"wp-block-list\"><li><strong>They are draft guidelines, not law.<\/strong> The framework was published for consultation. Final text and timelines for adoption are not fixed, and the patent office did not respond to media queries on the draft at the time of reporting.<\/li><li><strong>They do not shorten the 20-year patent term.<\/strong> India has not changed patent duration. The guidelines only tighten what qualifies for a <em>new<\/em> patent on an incremental change.<\/li><li><strong>They do not eliminate litigation risk.<\/strong> Interim injunctions remain available, and weak secondary patents can still buy delay. Faster examination does not guarantee faster market entry.<\/li><\/ul>\n\n\n<p class=\"wp-block-paragraph\">An industry counterpoint is also worth recording for balance: Nikkhil K Masurkar, CEO of Entod Pharmaceuticals, welcomed stricter scrutiny of incremental patents but argued that patent standards alone are insufficient, and called for a regulatory data protection framework to reward genuine clinical research &mdash; as reported by <em>LiveMint<\/em>. Buyers should expect this debate to continue alongside the guidelines.<\/p>\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n<h2 class=\"wp-block-heading\">&#x2705; Practical Takeaway for Importers<\/h2>\n\n\n<p class=\"wp-block-paragraph\">India&#8217;s direction of travel is clear: harder evidence requirements for incremental patents, a court system that has repeatedly cleared the path for generics on public-interest grounds, and a regulatory apparatus that increasingly codifies judicial precedent into routine examination. For buyers, that means more generic supply entering the market over the next two years &mdash; but arriving unevenly, with territorial and litigation constraints that differ product by product.<\/p>\n\n\n<p class=\"wp-block-paragraph\">The disciplined approach is to treat patent clearance and quality verification as two independent permissions. Neither substitutes for the other, and a supply relationship should not close until both are documented.<\/p>\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n<p class=\"wp-block-paragraph\">For a list of verified and reliable pharmaceutical distributors, refer to the <a href=\"https:\/\/indiamedicine.org\/?page_id=1454\">IMSDA&#8217;s verified member directory<\/a>.<\/p>\n\n\n<p class=\"wp-block-paragraph\">For more information, contact IMSDA at contact@indiamedicine.org.<\/p>\n\n","protected":false},"excerpt":{"rendered":"<p>India supplies roughly a fifth of the world&#8217;s generic medicines by volume, and much of that supply depends on a single legal question: when does a medicine actually become free to copy? For international buyers, importers and pharmacy operators, the answer changed shape in October 2026, when India&#8217;s patent office published new draft examination guidelines [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[19],"tags":[42,48,29,49],"class_list":["post-3722","post","type-post","status-publish","format-standard","hentry","category-knowledge","tag-cdsco","tag-generic-medicines","tag-india-pharmacy","tag-indian-pharma","entry"],"_links":{"self":[{"href":"https:\/\/indiamedicine.org\/index.php?rest_route=\/wp\/v2\/posts\/3722","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/indiamedicine.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/indiamedicine.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/indiamedicine.org\/index.php?rest_route=\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/indiamedicine.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=3722"}],"version-history":[{"count":0,"href":"https:\/\/indiamedicine.org\/index.php?rest_route=\/wp\/v2\/posts\/3722\/revisions"}],"wp:attachment":[{"href":"https:\/\/indiamedicine.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=3722"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/indiamedicine.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=3722"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/indiamedicine.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=3722"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}